Health authorities are issuing renewed alerts concerning the spread of a dominant Covid-19 subvariant now prevalent in several countries. While its clinical effect remains moderate at present, the variant’s transmission dynamics and genetic mutations have raised additional concerns.
The subvariant, designated Stratus (XFG), initially presents symptoms that may be mistaken for those associated with the common cold.
According to the World Health Organization (WHO), Stratus is derived from the Omicron lineage and integrates features from two antecedent variants, LF.7 and LP.8.1.2. Although first identified in January 2025, it was officially classified under the WHO's "Variants Under Monitoring" category as of June.
As reported by the WHO, XFG has been detected in 38 countries, accumulating 1,648 documented genetic sequences as of June 22. This variant now constitutes nearly one quarter of global samples analysed, having tripled in prevalence within a four-week period.
The latest data indicate that Southeast Asia exhibits the most substantial increase in cases linked to this strain, although community transmission has also been confirmed on other continents.
In comparison, the Nimbus variant (B.1.8.1), previously identified in the United States, accounted for 43% of infections in June, according to the Centres for Disease Control and Prevention (CDC). However, Stratus is now surpassing Nimbus in prevalence, distinguished predominantly by a higher number of spike protein mutations.
The WHO reports that Stratus possesses nine additional mutations in the spike protein, potentially enhancing its ability to evade antibodies conferred by prior infection or vaccination.
Global Risk Assessment: “Low”
Despite the rapid expansion of its global presence, the WHO currently assesses the risk posed by this subvariant to global public health as “low.” There is no current evidence to suggest increased severity of illness or mortality rates compared to previous variants.
Dr. Kaywaan Khan, cited by Cosmopolitan UK, affirms there are no indications of significant clinical deterioration relative to earlier strains, stating, “Stratus appears to be no worse than other recent versions of the virus in terms of hospitalizations or deaths.”
Primary Symptom: Hoarseness
While clinical manifestations may vary, one notable feature of Stratus is hoarseness. Dr. Khan notes, “One of the most noticeable symptoms of Stratus is dysphonia, a vocal change characterized by a harsh or raspy voice.”
This presentation differs from the Nimbus variant, which was associated with intense pharyngitis; Stratus appears to cause more nuanced symptoms.
Overall Clinical Profile Remains Consistent
In addition to hoarseness, the principal symptoms parallel those observed with earlier variants—fever, chills, fatigue, cough, nasal congestion, myalgia or headache, nausea, and anosmia or ageusia.
Although most cases remain mild, clinicians recommend diagnostic testing in case of uncertainty, particularly during periods when influenza and other respiratory viruses circulate.
Diagnostic Testing Remains Critical
“Regardless of symptom severity or resemblance to a cold, testing is essential to confirm or exclude a Covid-19 diagnosis,” emphasizes Dr. Khan.
He further advocates for continued surveillance, especially among high-risk or vulnerable groups, despite the reduction in severe cases. In response to the accelerating dissemination of XFG, the WHO has intensified monitoring efforts and updated guidance for national health authorities. Developments in the coming weeks will be instrumental in determining whether this rise represents a transient spike or a sustained trend.
Ongoing Recommendations
Standard preventive measures, including frequent hand hygiene, avoidance of poorly ventilated environments, and self-isolation upon symptom onset, remain recommended. Epidemiological surveillance and adherence to public health guidelines continue to be fundamental in preventing setbacks in pandemic control.
Source https://postal.pt/
